Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine monophosphate.
2-Amino-3-(hydroxynitrosoamino)propionic acid (alanosine), at a concentration as low as 2.7 muM, completely inhibits the incorporation of hypoxanthine into adenosine triphosphate by cultured Novikoff rat hepatoma cells. Alanosine inhibits the first step in the conversion of inosine monophosphate to adenosine monophosphate because inosine monophosphate, but not adenylosuccinate, accumulates in treated cells. However, the alanosine inhibition is not prevented by aspartic acid, even at a concentration of 1 mM. Alanosine treatment results in the inhibition of cell division, DNA synthesis, RNA and protein synthesis (in this order), and a depletion of the cells of adenosine triphosphate. Some of the cells accumulate in late G2 or M, but the remainder become arrested in other stages of the cell cycle. All effects are due to the inhibition of adenosine monophosphate synthesis and the consequent depletion of the adenosine triphosphate pool since they are completely prevented or reversed by addition of adenine, but not hypoxanthine, to the medium. Pyrimidine nucleotide synthesis is not significantly inhibited by alanosine, since the uridine triphosphate pool is not affected and uridine fails to reverse the cytotoxicity of alanosine. Alanosine also inhibits the transport of aspartic acid, but has a much lower affinity for this transport system than aspartic acid.
D000225:Adenine / Q000494:pharmacology; D000249:Adenosine Monophosphate / Q000096:biosynthesis* / Q000378:metabolism / Q000031:analogs & derivatives; D000255:Adenosine Triphosphate / Q000378:metabolism; D000409:Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D001224:Aspartic Acid / Q000378:metabolism / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002478:Cells, Cultured; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003864:Depression, Chemical; D005947:Glucose / Q000378:metabolism; D007042:Hypoxanthines / Q000378:metabolism; D007292:Inosine Nucleotides / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism*; D008574:Mengovirus / Q000187:drug effects; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009374:Neoplasms, Experimental / Q000378:metabolism; D009603:Nitroso Compounds / Q000494:pharmacology*; D011685:Purine Nucleotides / Q000096:biosynthesis; D011742:Pyrimidine Nucleotides / Q000096:biosynthesis; D012334:RNA, Neoplasm / Q000096:biosynthesis; D013386:Succinates / Q000378:metabolism; D014500:Uracil Nucleotides / Q000378:metabolism; D014529:Uridine / Q000378:metabolism / Q000494:pharmacology
D004273:DNA, Neoplasm; D007042:Hypoxanthines; D007292:Inosine Nucleotides; D009363:Neoplasm Proteins; D009603:Nitroso Compounds; D011685:Purine Nucleotides; D011742:Pyrimidine Nucleotides; D012334:RNA, Neoplasm; D013386:Succinates; D014500:Uracil Nucleotides; C012168:adenylosuccinate; C000082:alanosine; D001224:Aspartic Acid; D000249:Adenosine Monophosphate; D000255:Adenosine Triphosphate; D005947:Glucose; D000225:Adenine; D000409:Alanine; D014529:Uridine